POETIC: Trial of perioperative endocrine therapy – individualising care
Primary aim: To determine whether two weeks perioperative aromatase inhibitor (AI) therapy before and after surgery improves outcome compared with standard adjuvant therapy. Eligibility: Postmenopausal women with ER/PgR positive invasive breast cancer. Trial design: Phase III, multicentre, randomised trial Target accrual: 4350 patients Patients will be allocated in a 2:1 ratio to PERIOPERATIVE THERAPY with an AI for 4 weeks (two weeks before and two weeks after surgery) or NO PERIOPERATIVE THERAPY. Group I: PERIOPERATIVE THERAPY with an AI Choice of AI is according to centre policy and may be either anastrozole (1mg/day) or letrozole (2.5mg/day) Group II: NO PERIOPERATIVE THERAPY 4 weeks (two weeks before and two weeks after surgery)
- ICR Clinical Trials & Statistics Unit (ICR-CTSU) ICR-CTSU is a research-led, academic clinical trials unit (CTU) within the Division of Clinical Studies at the ICR. Our expertise spans the whole clinical trial life cycle. We receive core funding from Cancer Research UK, are a UK Clinical Research Collaborative (UKCRC) registered CTU and one of 15 CTUs recognised by the National Cancer Research Institute (NCRI) for professional specialism in the development and delivery of cancer trials. ICR-CTSU is committed to the responsible sharing of clinical trial data and trial samples with the wider research community in order to improve scientific and medical knowledge about cancer. To enable data and samples to be effectively shared with others, an access policy and defined procedure exist to ensure that relevant legal, ethical and commercial constraints are recognised and that data and samples are made available for new research purposes in a responsible manner. Please consult the data sharing page for further information.
The Institute of Cancer Research
15 Cotswold Road
|Year||Access Requests Received||Access Requests Approved|